argenx reported strong financial results for Q1 2025, with $807 million in total operating income

From GlobeNewswire: 2025-05-08 01:00:00

argenx SE reported $790 million in global product net sales for the first quarter of 2025. The company treated the first patients with VYVGART Hytrulo pre-filled syringe for self-injection in the US and Germany. CIDP global expansion was announced with a positive CHMP opinion for VYVGART-SC in the EU. The management will host a conference call today at 2:30 PM CET. argez continues to execute on its ‘Vision 2030’ to reach 50,000 patients across 10 labeled indications globally and advance its pipeline candidates into Phase 3 development by 2030.

Financially, the company generated $807 million in total operating income for the first quarter of 2025. Product net sales for VYVGART and VYVGART SC were $790 million. Operating expenses were $668 million, with research and development expenses accounting for $309 million. The company reported a profit of $169 million for the period. The financial guidance remains unchanged at approximately $2.5 billion.

argenx plans to continue advancing its pipeline candidates, including efgartigimod, empasiprubart, and ARGX-119. The company also aims to generate sustainable value through continued investment in its Immunology Innovation Program. Additionally, the company provided details of its financial results for the first quarter of 2025, showing a significant increase in total operating income compared to the same period in 2024.

The company will hold its Annual General Meeting of Shareholders on May 27, 2025, and will release its Half Year and Second Quarter 2025 Financial Results and Business Update on July 31, 2025. Investors are encouraged to tune in to the conference call and webcast today at 2:30 PM CET to learn more about argenx’s financial results and business update.



Read more at GlobeNewswire: argenx Reports First Quarter 2025 Financial Results and